Inegy

Simvastatin/Ezetimibe, the active ingredients in Inegy, are a combined HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as an oral tablet for adult use. They work together to lower elevated LDL‑cholesterol and total cholesterol in patients with hypercholesterolemia, mixed dyslipidemia, or primary hyperlipidemia. The fixed‑dose combination simplifies therapy and improves adherence compared with separate agents.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Inegy is indicated for lipid disorders and works to improve the cholesterol pathway.

Hypercholesterolemia: reduces LDL‑cholesterol levels and total cholesterol. Mixed dyslipidemia: lowers triglycerides and raises HDL‑cholesterol while decreasing LDL‑cholesterol. Primary hyperlipidemia: provides a fixed‑dose option to achieve target lipid goals in patients with elevated cholesterol.

Inegy may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Headache - Muscle pain or weakness - Abdominal discomfort - Diarrhea - Nausea

Serious or Rare Side Effects: - Rhabdomyolysis with renal failure - Severe liver injury (elevated transaminases) - Anaphylactic or severe allergic reactions

When prescribing Inegy, clinicians should consider several safety measures.

Liver function monitoring: assess baseline and periodic hepatic enzymes because both agents can affect liver. Muscle symptom vigilance: discontinue if unexplained muscle pain, tenderness or weakness with CK elevation. CYP3A4 inhibitor avoidance: avoid strong inhibitors such as itraconazole or clarithromycin. Pregnancy and lactation: use only if potential benefit justifies risk; safety not established. Renal impairment: dose adjustment may be required in severe renal dysfunction. Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Inegy interacts with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) – increase simvastatin exposure. - Gemfibrozil – markedly raises risk of myopathy and rhabdomyolysis. - Cyclosporine – elevates both simvastatin and ezetimibe plasma levels. - High‑dose niacin – potentiates muscle toxicity.

Moderate Interactions (Monitor Closely): - Amlodipine – may increase simvastatin concentrations modestly. - Warfarin – monitor INR as lipid‑lowering therapy can affect anticoagulation. - Digoxin – observe for altered serum levels when combined with ezetimibe.